ALUPENT
LOE ApproachingNDAORALTABLETPriority Review
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an oral tablet small-molecule drug approved in 1974 by Boehringer Ingelheim under NDA status. The specific mechanism of action and therapeutic indication are not publicly available in current datasets. This product represents a legacy pharmaceutical asset from the mid-20th century era.
LOE Approaching
With LOE approaching and minimal commercial data, this product is in wind-down mode with reduced team investment and limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero active job postings linked to ALUPENT indicate minimal hiring or expansion. Roles on this product are typically maintenance-focused with limited advancement potential or learning opportunities in modern drug development.
Brand ManagerRegulatory Affairs Specialist
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.